GnRH Antagonist Clinical Trial
Official title:
A Randomized Control Trial to Compare the Euploid Rate of Blastocyst Between the Progestin-primed Ovarian Stimulation Protocol and the GnRH Antagonist Protocol in Patients Undergoing PGT-A
This randomized trial aims to compare the euploid rate of blastocysts between PPOS and GnRH antagonist protocols in patients undergoing PGT-A. Infertile women who have medical indication for PGT-A will be recruited for study after explanation and counseling if they fulfill the inclusion criteria and do not have the exclusion criteria. Eligible women will be randomised into one of the two groups: Antagonist group: Women will receive antagonist once subcutaneously daily from day 6 of ovarian stimulation till the day of the ovulation trigger. PPOS group: Women will receive oral Duphaston 10mg bd from Day 3 till the day of ovulation trigger. The primary outcome is the euploidy rate of blastocysts.
Status | Recruiting |
Enrollment | 400 |
Est. completion date | December 1, 2025 |
Est. primary completion date | December 1, 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 20 Years to 43 Years |
Eligibility | Inclusion Criteria: - Age of women <43 years at the time of ovarian stimulation for IVF - Antral follicle count (AFC) >=5 on day 2-5 of the period - PGT-A indicated for advanced maternal age (>=38 years), recurrent miscarriage (>=2 consecutive miscarriage) and repeated implantation failure (>=4 embryos replaced or >=2 blastocysts replaced without success), recurrent foetal aneuploidy Exclusion Criteria: - Presence of a functional ovarian cyst with E2>100 pg/mL - Recipient of oocyte donation - Presence of hydrosalpinx or endometrial polyp which is not surgically treated |
Country | Name | City | State |
---|---|---|---|
China | Shanghai JiAi Genetics & IVF Institute | Shanghai | Shanghai |
Lead Sponsor | Collaborator |
---|---|
ShangHai Ji Ai Genetics & IVF Institute |
China,
Begueria R, Garcia D, Vassena R, Rodriguez A. Medroxyprogesterone acetate versus ganirelix in oocyte donation: a randomized controlled trial. Hum Reprod. 2019 May 1;34(5):872-880. doi: 10.1093/humrep/dez034. — View Citation
Kuang Y, Chen Q, Fu Y, Wang Y, Hong Q, Lyu Q, Ai A, Shoham Z. Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. Fertil Steril. 2015 Jul;104(1):62-70.e3. doi: 10.1016/j.fertnstert.2015.03.022. Epub 2015 May 5. — View Citation
Lee E, Illingworth P, Wilton L, Chambers GM. The clinical effectiveness of preimplantation genetic diagnosis for aneuploidy in all 24 chromosomes (PGD-A): systematic review. Hum Reprod. 2015 Feb;30(2):473-83. doi: 10.1093/humrep/deu303. Epub 2014 Nov 28. — View Citation
Massin N. New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF. Hum Reprod Update. 2017 Mar 1;23(2):211-220. doi: 10.1093/humupd/dmw047. — View Citation
Yu S, Long H, Chang HY, Liu Y, Gao H, Zhu J, Quan X, Lyu Q, Kuang Y, Ai A. New application of dydrogesterone as a part of a progestin-primed ovarian stimulation protocol for IVF: a randomized controlled trial including 516 first IVF/ICSI cycles. Hum Reprod. 2018 Feb 1;33(2):229-237. doi: 10.1093/humrep/dex367. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | euploidy rate | euploidy rate of blastocysts | 1 month after oocyte retrieval | |
Secondary | number of mature oocytes | number of MII oocytes | 1 day after oocyte retrieval | |
Secondary | number and grading of blastocysts | number and grading of blastocysts suitable for biopsy and freezing | 1 week after oocyte retrieval | |
Secondary | positive serum hCG | serum ß-hCG =10 mIU/mL of the first FET | 2 weeks after FET | |
Secondary | clinical pregnancy | presence of intrauterine gestational sac by trans-vaginal ultrasound at 6 gestational weeks of the first FET | 6 weeks' gestation | |
Secondary | implantation rate | the number of gestational sacs per blastocyst transferred of the first FET | 6 weeks' gestation | |
Secondary | biochemical pregnancy | positive serum hCG not followed by clinical pregnancy of the first FET | 6 weeks' gestation | |
Secondary | ongoing pregnancy | a viable pregnancy beyond 12 weeks' gestation of the first FET | 12 weeks' gestation | |
Secondary | live birth rate | deliveries =22 weeks gestation with heartbeat and breath of the first FET | 1 year after FET | |
Secondary | multiple pregnancy | more than one intrauterine sacs on scanning | multiple pregnancy beyond gestation 12 weeks | |
Secondary | ectopic pregnancy | pregnancy outside the uterine cavity | ectopic pregnancy during 12 weeks' gestation | |
Secondary | birthweight of newborns | the birth weight of newborns | 1 year after FET | |
Secondary | serum baseline FSH | baseline FSH of period day 2-3 | day 2-3 of period | |
Secondary | progesterone level on the trigger day | progesterone level on the trigger day | 2 days before oocyte retrieval | |
Secondary | estradiol level on the trigger day | estradiol level on the trigger day | 2 days before oocyte retrieval | |
Secondary | miscarriage | clinically recognised pregnancy loss before 22 weeks of pregnancy. | 22 weeks of pregnancy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04414761 -
Live Birth Rate Between PPOS and GnRH Antagonist Protocol in Patients With Anticipated High Ovarian Response
|
Phase 3 | |
Recruiting |
NCT03188471 -
Preventive Application of GnRH Antagonist on Early OHSS
|
Phase 4 | |
Recruiting |
NCT02201914 -
Clomiphene Citrate Plus Gonadotropins and GnRH Antagonist Versus Flexible GnRH Antagonist Protocol Versus Microdose GnRH Agonist Protocol in Poor Responders Undergoing IVF
|
Phase 4 | |
Completed |
NCT01286051 -
Single Injection of Ganirelix in Gonadotropin Intrauterine Insemination (IUI) Cycles
|
N/A | |
Not yet recruiting |
NCT05326087 -
Comparison of the Euploid Rate of Blastocyst Between PPOS and GnRH Antagonist Protocol in Women With PCOS Undergoing PGT-A
|
Phase 3 |